Tirzepatide: what happened to body weight?
The summary describes a trial in adults with obesity.
What did they want to find out?
They wanted to know whether people receiving tirzepatide lost weight.
What does this example say?
The example says weight fell on average. It also says some people left the trial because of digestive problems.
What does this mean for you?
An average describes the group. It does not say how much one person would lose.
What we still do not know
This example has no verified reference. The original paper needs checking to understand the results and the problems reported.
Show example study details (not verified)
These details come from an example summary. We have not checked the original paper. They are not proof that a product works or is safe.
Example summary: weekly tirzepatide in obesity
New England Journal of Medicine · 2022
How it was studied
Randomized, double-blind, placebo-controlled. n = 2,539 adults.
Original example finding
Up to 20.9% mean weight reduction with the highest dose over 72 weeks, according to the supplied summary.
Original example limitations
Unverified profile. Gastrointestinal effects led to discontinuation in a relevant minority.
Terms explained
- Average
- A result that describes the group, not each person.
- Gastrointestinal
- Related to the stomach and intestines.
This link opens PubMed's search site, not a checked paper for this summary.
Open PubMed (reference unverified)